363 filings
8-K
BCRX
Biocryst Pharmaceuticals Inc.
26 Feb 24
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
7:05am
8-K
BCRX
Biocryst Pharmaceuticals Inc.
18 Jan 24
Amendments to Articles of Incorporation or Bylaws
5:21pm
8-K
BCRX
Biocryst Pharmaceuticals Inc.
8 Jan 24
Results of Operations and Financial Condition
7:02am
8-K
BCRX
Biocryst Pharmaceuticals Inc.
1 Dec 23
Departure of Directors or Certain Officers
7:37am
8-K
BCRX
Biocryst Pharmaceuticals Inc.
30 Nov 23
Regulation FD Disclosure
9:04am
8-K
ws0bgp8e6 hwj6ce21k3
3 Nov 23
Regulation FD Disclosure
12:16pm
8-K
ap0ye84 xajyra
3 Nov 23
Regulation FD Disclosure
12:14pm
8-K
avhhdisec
2 Nov 23
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
b7g tph2bch7
26 Oct 23
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
9:36am
8-K
sp1a 4owyun
3 Aug 23
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
7:04am
8-K
42janpn1gyf
11 Jul 23
Departure of Directors or Certain Officers
7:00am
8-K
0eqs8lx
14 Jun 23
Departure of Directors or Certain Officers
7:02am
8-K
9mt459p6quyhjgp1m
3 May 23
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
7:08am
8-K
3w4k wj6ylpnltss
18 Apr 23
Entry into a Material Definitive Agreement
7:02am
8-K
esvu0w98ad5c j9
13 Mar 23
Regulation FD Disclosure
6:59am
8-K
pyoz2mb0xiiths 3l7j
21 Feb 23
BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
7:05am
8-K
pzibj
9 Jan 23
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance
7:10am
8-K
ep05q05 fs2gk
15 Dec 22
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
7:03am
8-K
clkq98966dy4ripm
1 Nov 22
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
7:06am
8-K
pf74zx
14 Sep 22
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
4:08pm